<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">28441993</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>02</Month>            <Day>12</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>02</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1539-6304</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>38</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2017</Year>                        <Month>May</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Allergy and asthma proceedings</Title>                <ISOAbbreviation>Allergy Asthma Proc</ISOAbbreviation>            </Journal>            <ArticleTitle>Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis.</ArticleTitle>            <Pagination>                <MedlinePgn>222-230</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2500/aap.2017.38.4050</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pharmacologic treatment is a mainstay of allergy therapy and many caregivers use over-the-counter antihistamines for the treatment of seasonal allergic rhinitis (SAR) symptoms in children.</AbstractText>                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the efficacy and safety of cetirizine 10 mg syrup versus loratadine 10 mg syrup versus placebo syrup in a randomized double-blind study of children, ages 6-11 years, with SAR.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">This randomized, double-blind, parallel-group, placebo-controlled study was conducted at 71 U.S. centers during the spring tree and grass pollen season. After a 1-week placebo run-in period, qualified subjects were randomized to once-daily cetirizine 10 mg (n = 231), loratadine 10 mg (n = 221), and placebo (n = 231) for 2 weeks. The primary efficacy end point was change from baseline in the subject's mean reflective total symptom severity complex (TSSC) score over 14 days.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Children treated with cetirizine experienced significantly greater TSSC score reductions versus children treated with placebo over 14 days (least square mean change, -2.1 versus -1.6; p = 0.006). The differences in TSSC score improvement over 14 days between the cetirizine versus loratadine groups (-2.1 versus -1.8; p = 0.124) and between the loratadine versus placebo groups (-1.8 versus -1.6; p = 0.230) were not statistically significant. Predominant adverse events in the cetirizine, loratadine, and placebo groups were headache (3.5, 3.6, and 3.1%, respectively) and pharyngitis (3.5, 2.7, and 3.5%, respectively). Somnolence was reported in three subjects (1.3%) treated with cetirizine and in none of the other subjects.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cetirizine 10 mg was statistically significantly more efficacious than placebo in the treatment of SAR symptoms in children ages 6-11 years. Symptom improvement was not significantly different between the loratadine 10 mg and placebo groups.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nayak</LastName>                    <ForeName>Anjuli S</ForeName>                    <Initials>AS</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Berger</LastName>                    <ForeName>William E</ForeName>                    <Initials>WE</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>LaForce</LastName>                    <ForeName>Craig F</ForeName>                    <Initials>CF</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Urdaneta</LastName>                    <ForeName>Eduardo R</ForeName>                    <Initials>ER</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Patel</LastName>                    <ForeName>Mitesh K</ForeName>                    <Initials>MK</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Franklin</LastName>                    <ForeName>Kathleen B</ForeName>                    <Initials>KB</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Mei-Miau</ForeName>                    <Initials>MM</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016448">Multicenter Study</PublicationType>                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Allergy Asthma Proc</MedlineTA>            <NlmUniqueID>9603640</NlmUniqueID>            <ISSNLinking>1088-5412</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018926">Anti-Allergic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>7AJO3BO7QN</RegistryNumber>                <NameOfSubstance UI="D017336">Loratadine</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>YO7261ME24</RegistryNumber>                <NameOfSubstance UI="D017332">Cetirizine</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="CommentIn">                <RefSource>Allergy Asthma Proc. 2017 May 1;38(3):167-169</RefSource>                <PMID Version="1">28441985</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D018926" MajorTopicYN="N">Anti-Allergic Agents</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017332" MajorTopicYN="N">Cetirizine</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017336" MajorTopicYN="N">Loratadine</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010612" MajorTopicYN="N">Pharyngitis</DescriptorName>                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006255" MajorTopicYN="N">Rhinitis, Allergic, Seasonal</DescriptorName>                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2017</Year>                <Month>4</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2017</Year>                <Month>4</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>2</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">28441993</ArticleId>            <ArticleId IdType="doi">10.2500/aap.2017.38.4050</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>